The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to provide a significant substantial decrease in body mass and enhance metabolic markers,